CLAUDIA GIULI SANTI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
bookPart Reações Medicamentosas(2016) SANTI, Claudia Giuli; DIAS, Natasha Favoretto; AVANCINI, João- Recurrent erythema multiforme: A therapeutic proposal for a chronic disease(2021) OLIVEIRA, Natasha Favoretto Dias de; MIYAMOTO, Denise; MARUTA, Celina Wakisaka; AOKI, Valeria; SANTI, Claudia GiuliRecurrent erythema multiforme is a chronic relapsing disease that represents a therapeutic challenge. Our objective was to retrospectively evaluate the clinical-epidemiological characteristics and therapeutic response of patients with recurrent erythema multiforme and suggest a therapeutic protocol. We included patients with recurrent erythema multiforme diagnosed between January 2000 and December 2019. Clinical symptoms and a positive serology for herpes simplex virus were the inclusion criteria to initiate acyclovir in monotherapy or a combined treatment with dapsone, thalidomide, or immunosuppressants in refractory cases. Thirty-five patients were included and 71.4% were female. The median disease onset age was 35.7 years and the mean follow-up was 7.58 years. The skin was the most affected site (91.4%). Herpes simplex virus immunoglobulin (Ig)G serology was positive in 91.1% of cases. Acyclovir treatment was used in 33 of 35 patients, and complete remission was achieved in 22 of 33 after the first therapeutic course; 16 of 22 relapsed and required a second acyclovir cycle. Combined treatment with dapsone was required in nine of 33 due to partial response to acyclovir; thalidomide was an adjuvant drug in four of 33 due to adverse effects to dapsone. After the first cycle of acyclovir with or without combined therapy, 19 of 33 patients relapsed and received 2-6 additional cycles. Our results suggest that recurrent erythema multiforme presents a good response to acyclovir in monotherapy or in combined therapy with dapsone or thalidomide in the majority of patients. We propose a long-term therapeutic protocol to enable disease remission.
conferenceObject Comparative analysis of the in situ interleukin 23/T-helper 17 lymphocyte axis cytokine profile in IgA pemphigus, subcorneal pustular dermatosis, and pustular psoriasis(2014) SIGNORELLI, Thais Helena Dias; MARUTA, Celina Wakisaka; SANTI, Claudia Giuli; SOTTO, Mirian Nacagami; DIAS, Natasha Favoretto; ROMITI, Ricardo; AOKI, Valeria- Plasmacytoid dendritic cells in dermatology(2021) OLIVEIRA, Natasha Favoretto Dias de; SANTI, Claudia Giuli; MARUTA, Celina Wakisaka; AOKI, ValeriaPlasmacytoid dendritic cells are part of the dendritic cells family and are a relevant link between innate and adaptive immunity. They are the most potent producers of type 1 interferon, generating antiviral response, stimulating macrophages and dendritic cells and inducing activation and migration of natural killer cells. Plasmacytoid dendritic cells also exert a role as antigen-presenting cells, promote T-lymphocyte responses, immunoregulation, plasma cells differentiation and antibody secretion. Even though plasmacytoid dendritic cells are not usually present in normal skin, their presence is detected in heating processes, viral infections, and inflammatory, autoimmune, and neoplastic diseases. In recent years, the presence of plasmacytoid dendritic cells in several dermatological diseases has been described, enhancing their potential role in the pathogenesis of such conditions. Future studies on the role of plasmacytoid dendritic cells in dermatology may lead to new therapeutic targets. (C) 2021 Sociedade Brasileira de Dermatologia.